01

Neoadjuvant Cemiplimab Hit 36% pCR in High-Risk CSCC Trial

NEO-CESQ: two cycles of neoadjuvant cemiplimab gave 36% pCR in high-risk head and neck CSCC; the NeoSquamos 10-gene signature flagged recurrence risk (AUC 0.838).